---
figid: PMC9699629__vaccines-10-01902-g001
pmcid: PMC9699629
image_filename: vaccines-10-01902-g001.jpg
figure_link: /pmc/articles/PMC9699629/figure/vaccines-10-01902-f001/
number: Figure 1
figure_title: ''
caption: 'Mechanistic actions of TXNIP on different immune cells drive cancer impediments.
  Note: Th17: T-helper 17; HIF: Hypoxia-inducible factors; GLUT1: glucose transporter
  1; TXNIP: Thioredoxin-interacting protein; Trx: Thioredoxin; ROS: Reactive oxygen
  species; NAD+: Nicotinamide adenine dinucleotide; G6P: Glucose 6 phosphate; PPP:
  Pentose phosphate pathway; IL: Interleukin; NADPH: Nicotinamide adenine dinucleotide
  phosphate; PAX: Paired box protein; MIF: Macrophage inhibiting factor; NF-κB: Nuclear
  factor kappa B; NLRP: NLR family pyrin domain containing; HDAC: histone deacetylases.'
article_title: 'Immunomodulatory Role of Thioredoxin Interacting Protein in Cancer’s
  Impediments: Current Understanding and Therapeutic Implications.'
citation: Ramkumar Katturajan, et al. Vaccines (Basel). 2022 Nov;10(11):1902.
year: '2022'

doi: 10.3390/vaccines10111902
journal_title: Vaccines
journal_nlm_ta: Vaccines (Basel)
publisher_name: MDPI

keywords:
- cancer
- immunomodulation
- immune cells
- TXNIP
- JAK-STAT
- AMPK
- PI3K/Akt

---
